Search

Your search keyword '"Evelyne Marry"' showing total 12 results
Start Over Author "Evelyne Marry" Topic business
12 results on '"Evelyne Marry"'

1. Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC)

Author

Catherine Faucher, Jean-Baptiste Thibert, John De Vos, Christine Giraud, Caroline Ballot, Valérie Mialou, Irina Ionescu, Marie-Thérèse Rubio, Bernard Dazey, Virginie Persoons, Eliane Gluckman, Chantal Kenzey, Jean-Hugues Dalle, Jérôme Larghero, Annalisa Ruggeri, Gérard Michel, Audrey Cras, Fernanda Volt, Jacques-Olivier Bay, Federico Garnier, Evelyne Marry, Vanderson Rocha, Fabienne Pouthier, Christian Chabannon, Hanadi Rafii, Eric Gautier, Danièle Bensoussan, Recherche clinique appliquée à l'hématologie ((EA_3518)), Université Paris Diderot - Paris 7 (UPD7), Centre Scientifique de Monaco (CSM), Agence de la biomédecine [Saint-Denis la Plaine], IRCCS San Raffaele Scientific Institute [Milan, Italie], Etablissement français du sang - Normandie (EFS), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] (EFS Bordeaux Nouvelle Aquitaine), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Etablissement Français du Sang Ile de France (EFS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Henry Mondor, Etablissement français du sang [Poitiers] (EFS), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Etablissement français du sang- Rhône-Alpes [Lyon], Etablissement Français du Sang [Grenoble] (EFS), Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC), Etablissement français du sang [Rennes] (EFS Bretagne), Hôpital Robert Debré Paris, Hôpital Robert Debré, Hôpital de la Timone [CHU - APHM] (TIMONE), Universidade de São Paulo = University of São Paulo (USP), CHU Clermont-Ferrand, Service d'Hématologie [CHRU Nancy], Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), and Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)

Subjects
medicine.medical_specialty, Bone marrow transplant, Multivariate analysis, [SDV]Life Sciences [q-bio], Umbilical cord, Cell therapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Biomedicine, Bone Marrow Transplantation, Transplantation, Neutrophil Engraftment, business.industry, Network on, Hematopoietic Stem Cell Transplantation, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Hematology, Fetal Blood, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cord blood, Blood Banks, Cord Blood Stem Cell Transplantation, business, 030215 immunology
Abstract

The public French Cord Blood Banks Network was established in 1999 with the objective of standardizing the practices governing umbilical cord blood (UCB) banking in France. The Network adopted a strategy to optimize its inventory and improve the quality of its banked units based on a quality improvement process using outcome data regularly provided by Eurocord. This study aimed to describe the results, over 10 years, of UCBT facilitated by a national network that used the same criteria of UCB collection and banking and to assess how modifications of banking criteria and unit selection might influence transplant outcomes. Nine hundred and ninety-nine units (593 single-unit and 203 double-unit grafts) were released by the Network to transplant 796 patients with malignant (83%) and non-malignant (17%) diseases. Median cell dose exceeded 3.5 × 107 TNC/kg in 86%. There was a trend to select units more recently collected and with higher cell dose. Neutrophil engraftment was 88.2% (85.7–90.7) and 79.3% (72.6–86.5) respectively for malignant and non-malignant diseases with a trend to faster recovery with higher cell doses. The respective 3-year transplant-related mortality were 31.1% (27.5–35.1) and 34.3% (27.0–43.5). OS was 49% ± 4 in malignant and 62% ± 4 in non-malignant disorders. In multivariate analysis, cell dose was the only unit-related factor associated with outcomes. Our results reflect the benefit on clinical outcomes of the strategy adopted by the Network to bank units with higher cell counts.

Published
2021
Full Text
View/download PDF

2. Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC)

Author

Catherine Faucher, Virginie Persoons, John De Vos, Caroline Ballot, Annalisa Ruggeri, Eric Gautier, Evelyne Marry, Eliane Gluckman, Jean-Baptiste Thibert, Marie-Thérèse Rubio, Jérôme Larghero, Danièle Bensoussan, Christian Chabannon, Fernanda Volt, Fabienne Pouthier, Christine Giraud, Jacques-Olivier Bay, Valérie Mialou, Irina Ionescu, Chantal Kenzey, Jean-Hugues Dalle, Hanadi Rafii, Marie Robin, Bernard Dazey, Audrey Cras, Mahamadou Sinayoko, Federico Garnier, Vanderson Rocha, Gérard Michel, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), and Université Clermont Auvergne (UCA)

Subjects
Bone marrow transplant, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Cell- and Tissue-Based Therapy, Cell therapy, Pandemic, Agency (sociology), Correspondence, Medicine, Humans, Intensive care medicine, Pandemics, Biomedicine, Transplantation, business.industry, SARS-CoV-2, Network on, Haematopoietic stem cells, Hematopoietic Stem Cell Transplantation, COVID-19, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Fetal Blood, Stem-cell research, Cord blood, Blood Banks, France, business
Abstract

International audience

Published
2021
Full Text
View/download PDF

3. Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor

Author

Evelyne Marry, Catherine Faucher, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Mohamad Mohty, Patrice Chevallier, Clémence Deteix, Alison M. Foote, Noel Milpied, Fabrice Larosa, Sabine Furst, Frédéric Garban, Ibrahim Yakoub-Agha, Anne Huynh, Sylvain Chantepie, Jean-Yves Cahn, Jacques-Olivier Bay, Régis Peffault de Latour, Nathalie Fegueux, Florence Mesnil, Hélène Labussière Wallet, Françoise Audat, Jean-Henri Bourhis, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), and Université Clermont Auvergne [2017-2020] (UCA [2017-2020])

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, Umbilical cord, 03 medical and health sciences, 0302 clinical medicine, Unrelated Donor, Internal medicine, medicine, Humans, Transplantation, Homologous, Sibling, Alternative donor, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, Transplantation, business.industry, Siblings, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, 3. Good health, Leukemia, Myeloid, Acute, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Stem cell, business, Unrelated Donors, 030215 immunology
Abstract

Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for high-risk acute myeloid leukemia. In the absence of an HLA-matched related or unrelated donor (MRD or MUD), the best alternative donor source remains controversial. Umbilical cord blood and haploidentical donors offer a time advantage when considering the duration from treatment indication to transplantation. This retrospective multicenter study of a French registry compares overall survival for alternative donor transplants in the 18 months following decision to transplant in the absence of a MRD between four groups of transplanted patients: MUD (control); HLA-mismatched MUD (mMUD); umbilical cord blood (UCB); and haploidentical (haplo). Between March 2012 and July 2016, 1302 patients were transplanted with MUD (n=803), mMUD (n=219), UCB (n=153) and haplo (n=127) donors. Multivariate analyses were conducted for overall survival 18 months after registration, overall survival after transplant, and transplant-related mortality, with adjustment for the several variables. After adjustment, the type of donor did not influence any of the three endpoints. Our results confirmed the significant negative impact of a longer time interval between registration and transplant: HR=1.04 [1.02–1.06] (p

Published
2020
Full Text
View/download PDF

4. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

Erik W. van Zwet, Jorge Sierra, Ibrahim Yakoub-Agha, Gillian Adams, Alois Gratwohl, Nigel Brook, Régis Peffault de Latour, Rafael F. Duarte, Yves Beguin, Carlos Solano, Arnon Nagler, Helen Baldomero, Noel Milpied, Christian Chabannon, Sylvia Montoto, Nina Worel, Francis Ayuk, Stephen R. Spellman, Mohamad Mohty, Kim Orchard, Theodor A. Balan, Jürgen Kuball, Urs Schanz, Evelyne Marry, Nicolaus Kroeger, Arjan C. Lankester, Ronald Brand, Leonie Wilcox, Gilles Macq, Jakob Passweg, Riccardo Saccardi, John Moore, Steven Tran, Selim Corbacioglu, J. Douglas Rizzo, Nicole Raus, Debra Gordon, Grzegorz W. Basak, Hein Putter, Jan Styczyński, Myriam Labopin, Per Ljungman, Harry Dolstra, Rachel Pearce, John A. Snowden, Hélène Poirel, Andreu Gusi, Francesca Bonifazi, Eoin McGrath, Liesbeth C. de Wreede, Julia Perry, Carmen Ruiz de Elvira, Fermín Sánchez-Guijo, Elena Oldani, Florence Mesnil, and UAM. Departamento de Medicina

Subjects
Feature, medicine.medical_specialty, Medicina, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], MEDLINE, 03 medical and health sciences, 0302 clinical medicine, Medicine, Medical physics, benchmarking, Bespoke, Accreditation, Haematological cancer, Transplantation, European Society for Blood and Marrow Transplantation (EBMT), business.industry, Marrow transplantation, Haematopoietic stem cells, Clinical performance, Autologous hsct, Hematology, Benchmarking, 3. Good health, FACT-JACIE standards, 030220 oncology & carcinogenesis, business, haematopoietic stem cell transplantation (HSCT), 030215 immunology
Abstract

In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT., The project was supported by funding from EBMT

Published
2019

5. Using EasyMatch(R) to anticipate the identification of an HLA identical unrelated donor: A validated efficient time and cost saving method

Author

Franck E. Nicolini, Stephane Morisset, Mauricette Michallet, Sophie Ducastelle, Valérie Mialou, C. Giannoli, Evelyne Marry, Hélène Labussière, Nathalie Tedone, Marie Y. Detrait, Fiorenza Barraco, Yves Bertrand, Valérie Dubois, Philippe Moskovtchenko, Sylvie Rey, Federico Garnier, Xavier Thomas, Mohamad Sobh, Sociétés, Acteurs, Gouvernement en Europe (SAGE), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Politique, Religion, Institutions et Sociétés : Mutations Européennes - Groupe de Sociologie Politique Européenne (PRISME-GSPE), Centre National de la Recherche Scientifique (CNRS), Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Du site actif au matériau catalytique (E3) (SAMCat ), Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Institut de Chimie du CNRS (INC)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Institut de Chimie du CNRS (INC), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL), Laboratoire d'hémathologie cellulaire - EFS BFC, Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Ecole de Technologie Supérieure [Montréal] (ETS), Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hôpital Edouard Herriot [CHU - HCL], Université de Poitiers-Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)

Subjects
Pediatrics, medicine.medical_treatment, Cost-Benefit Analysis, Histocompatibility Testing, Hematopoietic stem cell transplantation, Efficiency, Cohort Studies, 0302 clinical medicine, HLA Antigens, Bone Marrow, Immunology and Allergy, Medicine, Registries, Prospective cohort study, Child, Bone Marrow Transplantation, education.field_of_study, Hematopoietic Stem Cell Transplantation, General Medicine, 3. Good health, 030220 oncology & carcinogenesis, Histocompatibility, France, Unrelated Donors, Cohort study, Adult, medicine.medical_specialty, Patients, Cells, Immunology, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Donor Selection, Time, 03 medical and health sciences, blood, Humans, education, Retrospective Studies, business.industry, Donor selection, Retrospective cohort study, Surgery, Feasibility Studies, business, Laboratories, 030215 immunology
Abstract

International audience; In the absence of an HLA matched familial donor, a search for an unrelated donor or cord blood unit is initiated through worldwide registries. Although a first look-up on available HLA information of donors in the "book" at BMDW (Bone Marrow Donor Worldwide) can provide a good estimation of the number of compatible donors, the variety of resolution typing levels requires confirmatory typing (CT) which are expensive and time consuming. In order to help recipient centers in their work. The French donor registry (France Greffe de Moelle/Agence de la Biomedecine) has recently developed a software program called "EasyMatch(R)" that uses haplotype frequencies to compute the likelihood of phenotypic match in donors according to various typing resolution levels. The goal of our study is to report a single monocentric user-experience with EasyMatch(R), demonstrating that its routine use reduced the cost and the delay of the donor search in our center, allowing the definition of a new strategy to search compatible unrelated donors. The strategy was first established on a retrospective cohort of 217 recipients (185 adults and 32 children=before score) and then validated on a prospective cohort of 171 recipients (160 adults and 11 children=after score). For all patients, we calculated the delay between the registration day and the donor identification day, and the number of CT requested to the donor centre. Considering both groups, we could observe a significant decrease of the number of CT from 8 to 2 (p\textless0,001), and a significant decrease of the median delay to identify a suitable donor from 43 to 31days (p\textless0.0001). EasyMatch(R) estimates the number of potentially identical donors, but doesn't foresee availability of the donors. It provides us an easy tracking of mismatches, an estimation of the number of potential donors, the selection of population following ethnic origin of patients and a high prediction when probability is high or low. It affords a new approach of donor search in our daily work and improves the efficiency in the great challenge of the compatible donor identification

Published
2016
Full Text
View/download PDF

6. Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI)

Author

F Quainon, Evelyne Marry, C Retière, J.-F. Eliaou, A. Parissiadis, O Avinens, A Boudifa, Dominique Masson, N Legrand, Nicole Raus, Ibrahim Yakoub-Agha, A Batho, P Rettman, Florent Delbos, David Senitzer, Anne Kennel, A. Dormoy, Xavier Lafarge, Anne Devys, L. Absi, I Theodorou, M de Matteis, Anne Cesbron, M Drouet, Pascale Loiseau, Florent Malard, M Fort, Katia Gagne, Christophe Picard, Immunovirologie et polymorphisme génétique, Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), ArcelorMittal Maizières Research SA, ArcelorMittal, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang - Alpes-Méditerranée (EFS - Alpes-Méditerranée), Etablissement Français du Sang, Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC), Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] (EFS Bordeaux Nouvelle Aquitaine), Etablissement français du sang [Nice] (EFS), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire Paul Painlevé (LPP), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet - Saint-Étienne (UJM), Etablissement français du sang [Clermont-Ferrand] (EFS), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Etablissement français du sang [Caen], Ambiances, Architectures, Urbanités (AAU ), École Centrale de Nantes (ECN)-École nationale supérieure d'architecture de Nantes (ENSA Nantes)-École nationale supérieure d'architecture de Grenoble (ENSAG)-Ministère de la Culture et de la Communication (MCC)-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang - Grand Est (EFS - alsace strasbourg), Développement du Systeme Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Limoges, City of Hope National Medical Center, Registre France Greffe de Moelle [Saint-Denis La Plaine] (RFGM), Agence de la biomédecine [Saint-Denis la Plaine], Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Etablissement Français du Sang [Nantes], Biologie des Organismes et Ecosystèmes Aquatiques (BOREA), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Muséum national d'Histoire naturelle (MNHN)-Institut de Recherche pour le Développement (IRD)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA), Arcelor Research S.A, Arcelor, Laboratoire d'Immunologie, CHU Saint-Eloi, Anthropologie bio-culturelle, Droit, Ethique et Santé ( ADES ), Aix Marseille Université ( AMU ) -EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique ( CNRS ), Etablissement Français du Sang - Alpes-Méditerranée ( EFS - Alpes-Méditerranée ), Etablissement français du sang [Besançon] ( EFS ), Centre de Transfusion Sanguine Aquitaine-Limousin ( CTS AQUITAINE-LIMOUSIN ), Centre de Transfusion Sanguine, Etablissement français du sang [Nice] ( EFS ), Laboratoire Paul Painlevé - UMR 8524 ( LPP ), Université de Lille-Centre National de la Recherche Scientifique ( CNRS ), Groupe Immunité des Muqueuses et Agents Pathogènes ( GIMAP ), Université Jean Monnet [Saint-Étienne] ( UJM ), Centre d'Immunologie et de Maladies Infectieuses ( CIMI ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Ambiances architecturales et urbaines ( AAU ), Ministère de la Culture et de la Communication ( MCC ) -École nationale supérieure d'architecture de Grenoble ( ENSAG ) -École nationale supérieure d'architecture de Nantes ( ENSA Nantes ) -École Centrale de Nantes ( ECN ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'allergologie, Centre Hospitalier Universitaire d'Angers, Registre France Greffe de Moelle [Saint-Denis La Plaine] ( RFGM ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Biologie des Organismes et Ecosystèmes Aquatiques ( BOREA ), Université des Antilles ( UA ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut de Recherche pour le Développement ( IRD ) -Muséum National d'Histoire Naturelle ( MNHN ) -Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Laboratoire Paul Painlevé - UMR 8524 (LPP), Université Jean Monnet [Saint-Étienne] (UJM), Centre National de la Recherche Scientifique (CNRS)-Université de Lille, École nationale supérieure d'architecture de Nantes (ENSA Nantes)-Ministère de la Culture et de la Communication (MCC)-École nationale supérieure d'architecture de Grenoble (ENSAG)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Nantes (ECN), Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA)-Muséum national d'Histoire naturelle (MNHN)-Institut de Recherche pour le Développement (IRD)-Sorbonne Université (SU)-Université de Caen Normandie (UNICAEN), and Normandie Université (NU)-Normandie Université (NU)

Subjects
0301 basic medicine, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Human leukocyte antigen, 03 medical and health sciences, 0302 clinical medicine, Receptors, KIR, HLA Antigens, Transplantation Immunology, Humans, Medicine, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, Progenitor cell, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, Gynecology, Transplantation, [ SDV ] Life Sciences [q-bio], business.industry, Umbilical Cord Blood Transplantation, French, Retrospective cohort study, Hematology, medicine.disease, humanities, language.human_language, 3. Good health, Treatment Outcome, 030104 developmental biology, Graft-versus-host disease, Immunology, language, [SDV.IMM]Life Sciences [q-bio]/Immunology, Cord Blood Stem Cell Transplantation, France, Stem cell, business, 030215 immunology
Abstract

Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) and the Societe Francophone d’Histocompatibilite et d’Immunogenetique (SFHI)

Published
2016
Full Text
View/download PDF

7. HLA Association with Hematopoietic Stem Cell Transplantation Outcome: The Number of Mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 Is Strongly Associated with Overall Survival

Author

Valérie Dubois, Evelyne Marry, A. Dormoy, Virginia Lepage, Monique Bois, Marc Busson, Pascale Perrier, Jean-Pierre Jouet, Pascale Loiseau, L. Gebuhrer, Marie-Lorraine Balere, Denis Reviron, Didier Blaise, Dominique Masson, Ryad Tamouza, Dominique Charron, Agnès Moine, Katia Gagne, Jean-Denis Bignon, Colette Raffoux, Antoine Toubert, L. Absi, Zina Chir, and Isabelle Jollet

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Adolescent, Bone marrow transplantation, Survival, medicine.medical_treatment, GVHD, Graft vs Host Disease, Histocompatibility Testing, Human leukocyte antigen, Hematopoietic stem cell transplantation, Risk Assessment, Cohort Studies, HLA Antigens, Recurrence, immune system diseases, Internal medicine, medicine, Humans, Relapse, Child, Survival analysis, Proportional Hazards Models, Retrospective Studies, Transplantation, Proportional hazards model, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Infant, Hematology, Middle Aged, Survival Analysis, Confidence interval, HLA-A, KIR, HLA, Child, Preschool, Immunology, Female, business
Abstract

HLA matching between the donor and recipient improves the success of unrelated hematopoietic stem cell transplantation (HSCT). Because many patients in need of an unrelated transplant have only donors with mismatch, information is needed to evaluate the limits of HLA mismatching. We examined the association of survival, acute graft-versus-host disease (aGVHD) and relapse with HLA-A, -B, -C, -DRB, -DQB1, and -DPB1 mismatching in 334 patients coming from 12 French transplant centers and who received a non-T cell-depleted bone marrow graft from an unrelated donor. All patients were prepared with the use of myeloablative conditioning regimens. Our analyses demonstrate negative effects of HLA mismatching for either HLA-A, -B, -C, -DRB1, or -DQB1 loci on survival. Multivariate Cox analyses showed that a single mismatch was associated with a significant decrement in survival (P = .046, hazard ratio [HR] = 1.41, confidence interval [CI] 95% 1.1-1.98). The presence of multiple mismatches was worse for survival (P = .003, HR = 1.91, CI 95% 1.26-2.91) and severe aGVHD (grade III-IV) (P = .002, HR = 2.51, CI95% 1.41-4.46). The cumulative incidences of aGVHD and relapse in those HLA-A, -B, -C, -DRB1, and -DQB1 identical pairs with 2, 1, or 0 DPB1 incompatibilities were 63%, 50%, and 51%, and 12%, 27%, and 20%, respectively, but these differences were not statistically significant. Similar differences of aGVHD and relapse, but not statistically significant, were observed in those HLA-A, -B, -C, -DRB1, and -DQB1 identical pairs with DPB1 disparities classified into permissive or nonpermissive mismatches according to Zino’s classification based on a hierarchy of the immunogenicity of the HLA-DP molecules. “Missing killer cell immunoglobulin-like receptor (KIR) ligand” evaluated on the presence of HLA-C1, -C2, and Bw4 groups in the recipients was not associated with aGVHD, survival, and relapse in this cohort of non-T cell-depleted HSCT.

Published
2007
Full Text
View/download PDF

8. Is there any impact of HLA-DPB1 disparity in 10/10 HLA-matched unrelated hematopoietic SCT? Results of a French multicentric retrospective study

Author

Dominique Masson, Virginie Renac, Christophe Picard, I Theodorou, M de Matteis, J.-F. Eliaou, Ibrahim Yakoub-Agha, F Quainon, Evelyne Marry, Isabelle Jollet, B. Coeffic, A. Dormoy, Daniel Hanau, Béatrice Pédron, Françoise Hau, Pascale Perrier, Pascale Loiseau, V Moalic, Florent Delbos, Anne Cesbron, Valérie Dubois, M Fort, Françoise Dufossé, Nicole Raus, A Batho, Xavier Lafarge, Katia Gagne, L. Absi, Sophie Caillat-Zucman, Etablissement Français du Sang - Alpes-Méditerranée (EFS - Alpes-Méditerranée), Etablissement Français du Sang, Labex_Transplantex (Labex_Transplantex), Hématologie -Immunologie -Cibles thérapeutiques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Etablissement français du sang- Rhône-Alpes [Lyon], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Etablissement français du sang [Besançon] (EFS), Etablissement français du sang [Poitiers] (EFS), Laboratoire de Biologie Médicale [Rennes], Etablissement français du sang [Rennes] (EFS Bretagne), Etablissement français du sang - Auvergne-Rhône-Alpes (EFS), Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Centre de Transfusion Sanguine Aquitaine-Limousin (CTS AQUITAINE-LIMOUSIN), Centre de Transfusion Sanguine, Laboratoire d'Analyses de Biologie Médicale (LABM), Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS Alsace, Etablissement français du sang [Clermont-Ferrand] (EFS), Développement du Systeme Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Etablissement français du sang [Angers], Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet - Saint-Étienne (UJM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire de Génétique Moléculaire et d'Histocompatibilité [Brest], Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Etablissement français du sang [Nice] (EFS), Immunologie cellulaire et tissulaire, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Etablissement français du sang [Rouen], Etablissement français du sang [Caen], Service Immunologie Biologique [Paris], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Registre France Greffe de Moelle [Saint-Denis La Plaine] (RFGM), Agence de la biomédecine [Saint-Denis la Plaine], Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service greffe de moelle osseuse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Etablissement Français du Sang [Nantes], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Jean Monnet [Saint-Étienne] (UJM), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Morvan [Brest], CHU Toulouse [Toulouse], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Etablissement Français du Sang - Alpes-Méditerranée ( EFS - Alpes-Méditerranée ), Labex_Transplantex ( Labex_Transplantex ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Etablissement français du sang [Besançon] ( EFS ), Etablissement français du sang [Poitiers] ( EFS ), Etablissement français du sang [Rennes] ( EFS Bretagne ), Etablissement français du sang - Auvergne-Rhône-Alpes ( EFS ), Anthropologie bio-culturelle, Droit, Ethique et Santé ( ADES ), Aix Marseille Université ( AMU ) -EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique ( CNRS ), Centre de Transfusion Sanguine Aquitaine-Limousin ( CTS AQUITAINE-LIMOUSIN ), Laboratoire d'Analyses de Biologie Médicale ( LABM ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -EFS Alsace, Etablissement français du sang [Clermont-Ferrand] ( EFS ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Groupe Immunité des Muqueuses et Agents Pathogènes ( GIMAP ), Université Jean Monnet [Saint-Étienne] ( UJM ), Laboratoire d'Immunologie, CHU Saint-Eloi, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Etablissement français du sang [Nice] ( EFS ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -IFR113-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Registre France Greffe de Moelle [Saint-Denis La Plaine] ( RFGM ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), and Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Graft vs Host Disease, Human leukocyte antigen, Hematopoietic stem cell transplantation, Internal medicine, medicine, Humans, Child, HLA-DP beta-Chains, Aged, Transplantation, [ SDV ] Life Sciences [q-bio], HLA-DPB1, business.industry, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Hematology, Middle Aged, medicine.disease, Allografts, Confidence interval, 3. Good health, Graft-versus-host disease, surgical procedures, operative, Host vs Graft Reaction, Relative risk, Child, Preschool, Hematologic Neoplasms, Immunology, Female, HLA-DPB1 disparity, France, business, Unrelated Donors, Algorithms
Abstract

International audience; We retrospectively analyzed the impact of HLA-DPB1 mismatches in a large cohort of 1342 French patients who underwent 10/10 HLA-matched unrelated HSCT. A significant impact of HLA-DPB1 allelic mismatches (2 vs 0) was observed in severe acute GVHD (aGVHDIII-IV) (risk ratio (RR)=1.73, confidence interval (CI) 95% 1.09-2.73, P=0.019) without impact on OS, TRM, relapse and chronic GVHD (cGVHD). According to the T-cell epitope 3 (TCE3)/TCE4 HLA-DPB1 disparity algorithm, 37.6% and 58.4% pairs had nonpermissive HLA-DPB1, respectively. TCE3 and TCE4 disparities had no statistical impact on OS, TRM, relapse, aGVHD and cGVHD. When TCE3/TCE4 disparities were analyzed in the graft-vs-host or host-vs-graft (HVG) direction, only a significant impact of TCE4 nonpermissive disparities in the HVG direction was observed on relapse (RR=1.34, CI 95% 1.00-1.80, P=0.048). In conclusion, this French retrospective study shows an adverse prognosis of HLA-DPB1 mismatches (2 vs 0) on severe aGVHD and of nonpermissive TCE4 HVG disparities on relapse after HLA-matched 10/10 unrelated HSCT.Bone Marrow Transplantation advance online publication, 3 November 2014; doi:10.1038/bmt.2014.253.

Published
2015
Full Text
View/download PDF

9. Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry

Author

Anne Sirvent, Vanderson Rocha, Reza Tabrizi, Thierry Lamy, Stephane Morisset, Gérard Socié, Gérard Michel, Marie-Lorraine Balere, Nicole Raus, Evelyne Marry, Pierre Bordigoni, Sabine Furst, Bruno Lioure, Mauricette Michallet, Bernard Rio, Nathalie Dhedin, Didier Blaise, Sébastien Maury, Eliane Gluckman, Eric Deconinck, Mohamad Mohty, Ibrahim Yakoub-Agha, Natacha Maillard, Jean-Yves Cahn, Mohamad Sobh, Jacques-Olivier Bay, Nathalie Fegueux, Agnes Buzyn, Aline Schmidt-Tanguy, Marc Renaud, Marie Robin, Hélène Labussière Wallet, Federico Garnier, Loic Fouillard, Anne Huynh, Noel Milpied, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Service d'hématologie greffe [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service d'hématologie et oncologie médicale, Hôpital Lapeyronie-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes, Service d'hématologie, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Unité de Transplantation Médullaire, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Hôpital d'enfants, Département d'Hématologie et Oncologie Médicale, Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Institut Cochin (UMR_S567 / UMR 8104), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Service Hématologie, Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Hôpital Jean Bernard, TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Hematology, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-CHU Grenoble, Unité de transplantation médullaire et laboratoire d'oncologie moléculaire, CRLCC Jean Perrin, Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Microenvironnement et cancer (MiCa), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service d'onco-hématologie, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Agence de la biomédecine [Saint-Denis la Plaine], Clinical Research Unit, Haematology, CHU Bordeaux [Bordeaux], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Hematology, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER-UNICANCER, Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Lapeyronie, Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -hopital Jean Minjoz, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ) -Hôpital d'enfants, Assistance publique - Hôpitaux de Paris (AP-HP), Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre hospitalier universitaire de Poitiers ( CHU Poitiers ) -Hôpital Jean Bernard, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Hematology, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-CHU Grenoble, Université Toulouse III - Paul Sabatier ( UPS ), Microenvironnement et cancer ( MiCa ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Hematology

Subjects
Male, Cancer Research, Time Factors, Transplantation Conditioning, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, Umbilical cord, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Recurrence, Medicine, Cumulative incidence, Registries, 0303 health sciences, Hematology, Middle Aged, 3. Good health, Survival Rate, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, Reduced Intensity Conditioning, Hematologic Neoplasms, Female, Cord Blood Stem Cell Transplantation, Adult, medicine.medical_specialty, Cord, Adolescent, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, Genetics, Humans, Transplantation, Homologous, Molecular Biology, 030304 developmental biology, Aged, Retrospective Studies, business.industry, Umbilical Cord Blood Transplantation, Cell Biology, Neutrophil recovery, Surgery, Transplantation, business, Follow-Up Studies
Abstract

Allogeneic hematopoietic stem cell (HSC) transplantation is a curative treatment for many hematologic malignancies for which umbilical cord blood (UCB) represents an alternative source of HSCs. To overcome the low cellularity of one UCB unit, double UCB transplantation (dUCBT) has been developed in adults. We have analyzed the outcome of 136 patients who underwent dUCBT reported to the SFGM-TC registry between 2005 and 2007. Forty-six patients received myeloablative regimens, and 90 patients received reduced-intensity conditioning regimens. There were 84 cases of leukemia, 17 cases of non-Hodgkin lymphoma, 11 cases of myeloma, and 24 other hematologic malignancies. At transplantation, 40 (29%) patients were in complete remission. At day 60 after transplantation, the cumulative incidence of neutrophil recovery was 91%. We observed one UCB unit domination in 88% of cases. The cumulative incidence of day 100 acute graft-versus-host disease, chronic graft-versus-host disease, transplant-related mortality, and relapse at 2 years were 36%, 23%, 27%, and 28% respectively. After a median follow-up of 49.5 months, the 3-year probabilities of overall and progression-free survival were 41% and 35%, respectively, with a significant overall survival advantage when male cord engrafted male recipients. We obtained a long-term plateau among patients in complete remission, which makes dUCBT a promising treatment strategy for these patients.

Published
2013
Full Text
View/download PDF

10. First application of the EBMT risk score in double umbilical cord blood transplantation for hematologic malignancies: Significant impact on different outcomes

Author

Marie Robin, Franck E. Nicolini, Sabine Furst, Mauricette Michallet, Evelyne Marry, Vanderson Rocha, Mohamad Mohty, Mohamad Sobh, Ibrahim Yakoub-Agha, Nathalie Fegueux, Noel Milpied, Hélène Labussière Wallet, and Didier Blaise

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Cord Blood Stem Cell Transplantation, Hematologic Neoplasms, Risk Assessment, Disease-Free Survival, Young Adult, Risk Factors, Internal medicine, Genetics, Humans, Transplantation, Homologous, Medicine, Young adult, Molecular Biology, Survival rate, Aged, Framingham Risk Score, business.industry, Umbilical Cord Blood Transplantation, Follow up studies, Cell Biology, Hematology, Middle Aged, Surgery, Europe, Survival Rate, Female, business, Risk assessment, Follow-Up Studies
Published
2014
Full Text
View/download PDF

11. Impact of Antithymocyte Globulin-Containing Conditioning Regimens on Patients Undergoing Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Report From the SFGM-TC Group

Author

Natacha Maillard, Bruno Lioure, Pierre Bordigoni, Eric Deconinck, Mauricette Michallet, Alain Duhamel, Jean El-Cheikh, Nathalie Contentin, Audrey Simon, Evelyne Marry, Alice Garnier, Ibrahim Yakoub-Agha, Gandhi Damaj, Stephane Vigouroux, Mohamad Mohty, Gaelle Guillerm, Jacques-Olivier Bay, Simona Lapusan, Faezeh Legrand, and Marie Robin

Subjects
medicine.medical_specialty, Globulin, biology, business.industry, Incidence (epidemiology), Immunology, Cell Biology, Hematology, Malignancy, medicine.disease, Biochemistry, Transplantation, Graft-versus-host disease, Internal medicine, medicine, biology.protein, Cumulative incidence, Stem cell, business, Busulfan, medicine.drug
Abstract

Abstract 3035 Background: due to a risk of relapse of underlying disease in patients transplanted with progressive malignancy, the use of antithymocyte globulins (ATG), incorporated within the conditioning regimen prior to allogeneic stem cell transplantation (allo-SCT), is still controversial. We report here on a study of 245 consecutive patients transplanted between January 1999 and December 2009 in 26 French and Belgian centers for progressive MDS, defined as stable, untreated, relapsed or refractory disease. Patients and Methods: Inclusion criteria included patients aged over 18 who received allo-SCT from either a sibling (n=153) or HLA-A, -B, -C, -DRB1 and -DQB1 allele matched unrelated donor (10/10) (n=86) for MDS or AML/RAEB-t (with 20–30% BM blasts). Data quality was ensured using computerized discrepancy errors and vigorous on-site data verification of every single file. A qualified research technicien has been appointed by the University-Hospital of Lille to assist on-site centers that couldn't meet data quality requirements. HLA matching was double-checked by the French Bone Marrow Donor Registry. Results: The first 239 files analyzed until now are presented, including 154 males and 85 females. According to the WHO classification at diagnosis, 85 patients had RA/RARS/RCMD, 86 RAEB1, 62 REAB2 and 6 RAEB-t/AML. Sixty-six patients had progressed to a more advanced disease before allo-SCT. At diagnosis, 102 patients had an IPSS int-2 or higher. Cytogenetic IPSS was recorded as favorable (n=109), intermediate (n=61), unfavorable (n=63) and missing (n=6). Disease status at transplant was established as follows: relapsed or refractory disease (n=106) and untreated or stable disease without hematological improvement (n=133). Median age at transplantation was 53 years (range, 20–70). Patients received myeloablative conditioning (n=105) and nonmyeloablative (n=134) including busulfan-based regimens (n=127), TBI-based regimens (n=92) or other alkylating-agent-based regimens (n=20). In this series, 95 patients (40%) received ATG as part of conditioning ('ATG' group), whereas 144 did not ('no-ATG' group). The analysis reference date of April 1st 2011, median follow-up in survivors was 50 months (IQR, 33–92) with 59 patients having died of relapse and 77 of TRM. The estimated 3-year OS and EFS was respectively 42.3%, and 32.4%. The probability of relapse, overall and event-free survival at 3 years was not significantly different between the two groups. In contrast, the cumulative incidence of grade 2–4 acute GVHD was 48% in the no-ATG group and 30% ATG group (P In conclusion, the addition of ATG to the conditioning regimen resulted in a decreased incidence of acute GVHD without increasing relapse rates and compromising patient survival undergoing allo-SCT for progressive MDS. Disclosures: Yakoub-Agha: Genzyme: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Research Funding; Fresinus: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria. Michallet:Genzyme: Honoraria, Membership on an entity's Board of Directors or advisory committees; Fresinus: Honoraria, Membership on an entity's Board of Directors or advisory committees. Deconinck:Celgene: Honoraria. Mohty:Genzyme: Honoraria, Membership on an entity's Board of Directors or advisory committees.

Published
2011
Full Text
View/download PDF

12. The Use of Bone Marrow Graft for Hematopoietic Stem Cell Transplantation From Matched Unrelated Donors After Reduced Intensity Conditioning Regimen Improves Survival : Analysis of the Societe Française De Greffe De Moelle Et De Therapie Cellulaire

Author

Anne Sirvent, Frédéric Garban, Jean-Paul Vernant, Gérard Socié, Marc Renaud, Agnes Buzyn, Denis Guyotat, Marie-Lorraine Balère-Appert, Noel Milpied, Pierre Bordigoni, Nathalie Contentin, Evelyne Marry, Mauricette Michallet, Jean-Michel Boiron, Didier Blaise, Andrea Toma, and Eric Deconinck

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunology, Context (language use), Cell Biology, Hematology, Hematopoietic stem cell transplantation, medicine.disease, Biochemistry, Surgery, Transplantation, Regimen, Graft-versus-host disease, medicine.anatomical_structure, Median follow-up, Internal medicine, medicine, Bone marrow, business, Survival analysis
Abstract

Abstract 873 The use of peripheral blood stem cells (PBSC) for hematopoietic stem cell transplantation (HSCT) is associated with a higher risk of chronic graft versus host disease (GvHD) but its impact on survival is not clear since it may favor a greater graft versus leukemia (GvL) effect. However, in the context of HSCT from unrelated donors (UD), the balance between GvH and GvL may differ from the context of sibling donors and thus the use of PBSC may be deleterious. In this retrospective study, we analyzed 103 patients from the french registry who received a graft from an UD after a reduced intensity conditioning regimen (RIC) to evaluate the role of various parameters including the source of stem cells on the outcome. Seventy-one D/R pairs (69%) were 10/10 HLA match at the allelic level. Mismatches concerned 5, 6, 15, 2 and 7 D/R pairs for HLA-A, -B, -C, -DRB1 and -DQB1, respectively. The median age was 46 years (18-67). All patients had hematologic malignancies: AL (n=35), MM (n=18), CLL (n=5), NHL (n=11), HD (n=9), CML (n=12), MDS (n=9), and MPS (n=4). 39% of the patients were in an advanced phase of the disease at time of HSCT. The conditioning regimen was Fluda/TBI 2Gys for 26 patients, Bu/Fluda/ATG for 24 patients, Fluda/Melph for 16 patients and others for 37 patients. Overall, anti-thymocytes globulins (ATG) were part of the conditioning regimen for 77% of patients. The source of stem cells was PBSC for 65 patients and bone marrow (BM) for 38 patients. The median follow up of the cohort is 61,3 months (1,2-113,7). The results showed that 95% of patients engrafted. Five patients did not engraft (4 in the BM group and 1 in the PBSC group). Acute GvHD grade II to IV and grade III/IV occurred in 47% and 19% of patients, respectively. The risk of developing chronic GvHD was 49% at 2 years. Overall survival (OS) was 36% at five years. The median disease free survival (DFS) was 55 months among the 36 patients alive. We performed univariate and multivariate analysis of factors susceptible to impact on GvHD and survival. The multivariate analysis included the impact of HLA mismatch, disease status, diagnosis, source of stem cells, patient's and donor's ages. This multivariate analysis performed on the global population shows a trend towards an improved OS with the use of BM instead of PBSC. However, when focusing the multivariate analysis on the 71 patients transplanted with a 10/10 match donor, the most potent factor influencing the outcome is the use of BM which is associated with an improved OS (p=0.03) and DFS (p=0.02), less acute GvHD grade II-IV (p=0.05), or grade III/IV (p=0.05) and less chronic GvHD (p=0.05). These results suggest that the use of BM as the source of stem cells should be reconsidered in the context of matched UD after RIC transplantation. Disclosures: No relevant conflicts of interest to declare.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results